Keyphrases
Real Patients
100%
Advanced Breast Cancer
100%
Atezolizumab
100%
Nab-paclitaxel
100%
Confidence Interval
28%
Overall Survival
28%
Progression-free Survival
28%
Programmed Death-ligand 1 (PD-L1)
28%
IMpassion130
28%
Population-based Study
14%
Breast Cancer Patients
14%
Phase II Trial
14%
Oncologic
14%
Advanced Disease
14%
Survival Outcomes
14%
Estrogen Receptor
14%
Epidermal Growth Factor Receptor
14%
Median Overall Survival
14%
Median Progression-free Survival
14%
Capital Region
14%
Human Epidermal Growth Factor Receptor 2-negative
14%
Research Overview
14%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Paclitaxel
100%
Atezolizumab
100%
Overall Survival
42%
Progression Free Survival
42%
Programmed Death 1 Ligand 1
28%
Disease
14%
Estrogen Receptor
14%
Epidermal Growth Factor Receptor 2
14%
Gamma Urogastrone
14%